上海君澜律师事务所 上海君澜律师事务所 关于 中安科股份有限公司 关于中安科股份有限公司 注销、回购注销、行权及解除限售相关事项 之 法律意见书 二〇二五年五月 上海君澜律师事务所 法律意见书 注销、回购注销、行权及解除限售相关事项之 法律意见书 致：中安科股份有限公司 上海君澜律师事务所（以下简称"本所"）接受中安科股份有限公司（以 下简称"公司"或"中安科"）的委托，根据《上市公司股权激励管理办法》 （以下简称"《管理办法》"）《中安科股份有限公司 2023 年股票期权与限制 性股票激励计划》（以下简称"《激励计划》"或"本次激励计划"）的规定， 就中安科本次激励计划注销部分股票期权、回购注销部分限制性股票、股票期 权第二期行权条件及限制性股票首次授予第二期及预留授予第一期解除限售条 件成就相关事项（以下简称"本次注销、回购注销、行权及解除限售"）相关 事项出具本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法 律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及 本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定 ...

Core Viewpoint - The company announced the cancellation of certain stock options due to unmet performance conditions and the departure of some incentive recipients, impacting the 2022 stock option incentive plan [1][14][16]. Summary by Sections Stock Option Incentive Plan Overview - The 2022 stock option incentive plan was approved at the first extraordinary general meeting, allowing for a total of 33,000,000 stock options to be granted [1][4]. - The plan includes four exercise periods with specific performance targets based on net profit growth from 2021 [1][3]. Performance Conditions - For the first exercise period, the net profit growth rate must be at least 24% for 2022; for the second, at least 66% for 2023; for the third, at least 180% for 2025 [2][3]. - If the performance targets are not met, the corresponding stock options will be canceled [3][14]. Adjustments and Cancellations - Due to the departure of 23 recipients and performance issues, a total of 31,593,126 stock options will be canceled, including 2,657,855 options from departing recipients and 28,935,271 options due to unmet performance conditions [14][16]. - The exercise price for the stock options has been adjusted multiple times, currently set at 5.67 yuan per share [12][14]. Impact on the Company - The cancellation of stock options is not expected to affect the implementation of the 2022 incentive plan or the stability of the core management team, nor will it have a substantial impact on the company's financial status and operational results [14][15]. Legal and Procedural Compliance - The company has ensured that the cancellation process complies with relevant laws and regulations, and necessary approvals have been obtained [16][17].

Core Viewpoint - The Supervisory Board of Keda Intelligent Technology Co., Ltd. has verified the eligibility and compliance of the company's 2025 Restricted Stock Incentive Plan, concluding that the plan meets all relevant legal and regulatory requirements [1][2][3] Group 1: Eligibility and Compliance - The company has the necessary qualifications to implement the stock incentive plan, as it has not received negative or unqualified audit opinions on its financial reports or internal controls in the last fiscal year [1][2] - The incentive plan does not include independent directors, supervisors, foreign personnel, or shareholders holding more than 5% of the company's shares, ensuring compliance with the relevant regulations [2][3] - The granting and vesting arrangements for the restricted stocks do not violate any laws or regulations and do not infringe on the interests of the company and its shareholders [3] Group 2: Implementation Process - The relevant proposals of the incentive plan must be submitted for approval at the company's shareholders' meeting before implementation [3] - The company will publicly disclose the names and positions of the incentive plan participants at least 10 days prior to the shareholders' meeting [2]

证券代码：603893 证券简称：瑞芯微 公告编号：2025-051 ? 回购注销原因：瑞芯微电子股份有限公司（以下简称"公司"）2022 年 股票期权与限制性股票激励计划首次授予限制性股票第三个限售期的公司层面 业绩考核未达标，解除限售条件未成就，公司董事会同意对 2022 年股票期权与 限制性股票激励计划首次授予的 3 名激励对象第三个限售期未达到解除限售条 件的 28,000 股限制性股票进行回购注销。 ? 本次注销股份的有关情况 瑞芯微电子股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次限制性股票回购注销的决策与信息披露 第四次会议，审议通过《关于 2022 年股票期权与限制性股票激励计划首次授予 第三个行权期行权条件及第三个限售期解除限售条件未成就暨注销股票期权和 回购注销限制性股票的议案》。鉴于公司 2022 年股票期权与限制性股票激励计 划首次授予限制性股票第三个限售期的公司层面业绩考核未达标，解除限售条件 未成就，公司董事会审议决定回购注销 2022 年股票期权与限制性股票 ...

Summary of Key Points Core Viewpoint - The company has publicly announced the list of individuals who will be granted restricted stock under its first A-share incentive plan, confirming that all selected individuals meet the necessary qualifications and conditions as per relevant regulations and internal guidelines [1][2]. Disclosure Situation - The company conducted an internal public announcement from May 30, 2025, to June 8, 2025, regarding the names and positions of 158 individuals selected for the initial grant of restricted stock. No objections were raised during the public announcement period [1]. Verification Opinion - The supervisory board of the company has verified that the selected individuals meet the criteria set forth in the relevant laws, regulations, and the company's incentive plan. There are no disqualifications as per the applicable guidelines, and none of the selected individuals are independent directors, supervisors, or major shareholders [2].

Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total repurchase amount ranging from RMB 5 million to RMB 10 million, aimed at implementing equity incentives or employee stock ownership plans [1][4][6]. Summary by Relevant Sections Repurchase Plan Details - The repurchase amount is set between RMB 5 million and RMB 10 million [1][4]. - The funding source for the repurchase will be the company's own funds [1][4]. - The maximum repurchase price is capped at RMB 30 per share, which does not exceed 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6]. - The repurchase will be conducted through the Shanghai Stock Exchange's trading system [1][5]. - The duration for the repurchase is within 12 months from the board's approval date [1][4]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for implementing equity incentives or employee stock ownership plans [1][4][8]. - If the company fails to implement these plans within three years after the repurchase, the unutilized shares will be canceled [1][4][12]. Shareholder and Management Plans - Major shareholders, including the actual controller and board members, have no plans to reduce their holdings in the next three to six months [2][10][11]. - The proposal for the repurchase was initiated by the actual controller and chairman, Mr. Cao Lin, based on confidence in the company's future development [12][13]. Financial Impact and Structure Changes - As of March 31, 2025, the company's total assets were RMB 5.266 billion, with net assets attributable to shareholders at RMB 3.901 billion [8]. - The repurchase amount, if at the upper limit of RMB 10 million, would represent approximately 0.02% of total assets and 0.26% of net assets [8]. - The repurchase is expected to have no significant impact on the company's operations, financial status, or future development [8]. Compliance and Authorization - The repurchase plan has been approved by more than two-thirds of the board members and does not require shareholder meeting approval [3][4]. - The management is authorized to handle all matters related to the repurchase, including adjustments to the plan as necessary [13][14].

Core Viewpoint - The legal opinion letter from Yuanwen (Shanghai) Law Firm confirms the legality and compliance of Suzhou Mingzhi Technology Co., Ltd.'s differentiated dividend distribution for the fiscal year 2024, ensuring it aligns with relevant laws and regulations [1][8]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is necessitated by the company's repurchased shares, which do not participate in profit distribution as per the relevant laws and regulations [4][5]. - The company plans to distribute a cash dividend of 4.50 yuan per 10 shares (including tax), excluding the 534,750 shares held in the repurchase account from this distribution [5][6]. - The total number of shares eligible for profit distribution is calculated to be 123,421,322 shares after excluding the repurchased shares from the total share capital of 123,956,072 shares [6][7]. Group 2: Legal Compliance and Verification - The law firm has conducted thorough verification of the legal compliance of the differentiated dividend distribution, ensuring no false records or misleading statements exist [2][3]. - The legal opinion letter serves as a necessary legal document for the company's differentiated dividend distribution and is subject to legal responsibility by the law firm [2][3]. - The law firm emphasizes that it only provides opinions on legal matters related to the differentiated dividend distribution and does not assess accounting or financial aspects [3][4].

中信证券股份有限公司 关于辽宁成大生物股份有限公司 以集中竞价交易方式回购公司股份的核查意见 中信证券股份有限公司（以下简称"保荐机构"或"中信证券"）作为辽宁 成大生物股份有限公司（以下简称"成大生物"或"公司"）首次公开发行股票 并在科创板上市的持续督导保荐机构，根据《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》《上海证券 交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，对公司以集 中竞价交易方式回购股份的事项进行了核查，具体情况如下： 一、回购方案的审议及实施程序 金通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人 民币普通股（A股）股票。具体内容详见 公司在上海证券交易所网站 （www.sse.com.cn）披露的《辽宁成大生物股份有限公司关于公司董事长提议回 购公司股份的提示性公告》（公告编号：2025-032）。 以集中竞价交易方式回购公司股份方案的议案》。公司全体董事出席会议，表决 结果为9票同意、0票反对、0票弃权，经三分之二以上董事出席的董事会会议决 议通过。根据《上市公司股份回购规则》及《公司章程》之规定，本 ...

一、会议按照法律、法规、有关规定和《公司章程》的规定进行， 参会人员应自觉维护会议秩序。 二、股东参加股东大会，依法享有发言权、质询权、表决权等权 利，并应认真履行法定义务，不得侵犯其他股东的合法权益。 三、参会股东或股东代表应在2025年6月23日上午9时—11时，下 午14时—16时到黑龙江珍宝岛药业股份有限公司（以下简称"公司"） 或者通过电子邮件等形式办理参会登记。已办理参会登记的股东及股 东代表需携带身份证明、股票账户卡、授权委托书等原件于2025年6 月25日下午13:55前到哈尔滨市平房开发区烟台一路8号办公楼办理 签到登记后参会。 四、股东提问应举手示意，并按照主持人的安排进行。发言及提 问前应先介绍自己的股东身份（或所代表的股东单位）、持股数量等 情况。发言及提问应围绕本次会议议案，每位发言时间不超过3分钟。 议案表决开始后将不再安排发言。 黑龙江珍宝岛药业股份有限公司 | 会 | 议 | | --- | --- | | 资 | | 料 议案 7：关于 2025 年向金融机构申请授信额度及融资的议案 .... 11 议案 9：关于董事、高级管理人员 2024 年度薪酬情况及 2025 年度薪 ...

Core Viewpoint - The article highlights promotional membership offers and educational courses related to investment banking and corporate finance, emphasizing significant discounts and a variety of learning opportunities for professionals in the field [2][4][6]. Membership Offers - Various membership options are available at discounted prices, including: - Annual Card: ¥4099, now ¥2799 - Semi-Annual Card: ¥2599, now ¥1799 - Honor Card: ¥1499, now ¥999 - Monthly Card: ¥699, now ¥599 [1]. Educational Courses - A range of courses is offered for free or at reduced prices, covering essential topics in investment banking and corporate finance, such as: - Mergers and Acquisitions Practicalities - Corporate Compliance Practices - Private Equity Fund Practices - AI Applications in Investment Banking [4][7][8]. - Specific courses include: - Mergers and Acquisitions with 140 case studies (4.9 hours) at ¥199.5 - Corporate Governance Compliance Issues (1.5 hours) at ¥84.5 - Financial Valuation Modeling from beginner to advanced (7.4 hours) at ¥149.5 [7][8]. Promotional Period - The promotional period for membership and courses runs from June 19 to June 26, with special pricing for two-year memberships at ¥3299 [2][8].